A Multinational, Multicenter Randomized Double-Blind, Parallel-Group, Placebo-Controlled Study, to Evaluate the Efficacy, Tolerability and Safety of Two Doses of, Oral Laquinimod in Relapsing Remitting (R-R) Multiple Sclerosis (MS) Subjects

Trial Profile

A Multinational, Multicenter Randomized Double-Blind, Parallel-Group, Placebo-Controlled Study, to Evaluate the Efficacy, Tolerability and Safety of Two Doses of, Oral Laquinimod in Relapsing Remitting (R-R) Multiple Sclerosis (MS) Subjects

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Mar 2015

At a glance

  • Drugs Laquinimod (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 14 Mar 2012 Planned end date changed from 1 Jun 2015 to 1 Jun 2014 as reported by ClinicalTrials.gov.
    • 21 Sep 2010 Results from the extension study showing a sustained positive benefit-risk profile of laquinimod were published online by the journal Multiple Sclerosis, according to a Teva Pharmaceutical Industries and Active Biotech media release.
    • 09 Sep 2009 Results have been presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top